Publications by authors named "Mourad Mseddi"
Background And Objective: Trough abiraterone concentration (ABI C) of 8.4 ng/mL has been identified as an appropriate efficacy threshold in patients treated for metastatic castration-resistant prostate cancer (mCRPC). The aim of the phase II OPTIMABI study was to evaluate the efficacy of pharmacokinetics (PK)-guided dose escalation of abiraterone acetate (AA) in underexposed patients with mCRPC with early tumour progression.
View Article and Find Full Text PDFArticle Synopsis
- Aprepitant, an antiemetic drug, has been linked to cases of encephalopathy when combined with ifosfamide, potentially due to its effects on metabolic pathways.
- The study analyzed the pharmacokinetics of ifosfamide and its metabolites in 42 patients with soft tissue sarcomas, comparing data from cycles with and without aprepitant.
- The results showed that aprepitant did not significantly alter the pharmacokinetic parameters of ifosfamide or its metabolites, although some other metabolites were not assessed.
Seven tyrosine kinase inhibitor compounds with anti-angiogenic properties remain key drugs to treat advanced renal cell carcinoma. There is a strong rationale to develop therapeutic drug monitoring for these drugs. General considerations of such monitoring of the several groups of anticancer drugs are given, with a focus on oral therapy.
View Article and Find Full Text PDF